# A Study to Evaluate the Effect of a Potent Cytochrome P450 (CYP) 3A Inhibitor on Ipatasertib

> **NCT03222310** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 15 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Ipatasertib
- **DRUG:** Itraconazole

## Key facts

- **NCT ID:** NCT03222310
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-18
- **Primary completion:** 2017-09-06
- **Final completion:** 2017-09-06
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2017-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03222310

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03222310, "A Study to Evaluate the Effect of a Potent Cytochrome P450 (CYP) 3A Inhibitor on Ipatasertib". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03222310. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*